On June 4, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced the launch of its aflibercept biosimilar, AHZANTIVE®, in Europe. According to Teva’s press release, the launch of AHZANTIVE® pre-filled syringes across European markets commenced in May 2026. The launch follows Teva’s semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG in Europe and Israel
Latest Post
More Posts
FDA Issues Draft Guidance on Safety Testing for Gene Editing Therapies
FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars
Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar
European Biosimilar Updates
Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe
Sun Pharma Launches ILUMYA® in India
Regeneron Seeks to Bifurcate or Stay Amgen’s Antitrust Claims in Aflibercept Patent Litigation
FDA Approves Denosumab Biosimilars BILDYOS and BILPREVDA
PTAB Discretionarily Denies Two Petitions, Refers a Third to the Board in Amgen v. Bristol-Myers Squibb
Subscribe: Subscribe via RSS
Blogs
Firm/Org